Deferasirox

CAS No.	201530-41-8	Cat. No.	BCP05341
Name	Deferasirox
Synonyms	ICL670; IC-L670; ICL 670; ICL-670A; ICL670A; ICL 670A; CGP-72670; CGP72670;CGP 72670;
Formula	C21H15N3O4	M. Wt	373.36

Description	Deferasirox's main use is to reduce chronic iron overload in patients who are receiving long-term blood transfusions for conditions such as beta-thalassemia and other chronic anemias. Deferasirox is the first oral medication approved in the USA for this purpose. The half-life of deferasirox is between 8 and 16 hours allowing once a day dosing. Two molecules of deferasirox are capable of binding to 1 atom of iron which are subsequently eliminated by fecal excretion. Its low molecular weight and high lipophilicity allows the drug to be taken orally unlike desferoxamine which has to be administered by IV route (intravenous infusion). Together with deferiprone, deferasirox seems to be capable of removing iron from cells (cardiac myocytes and hepatocytes) as well as removing iron from the blood.
Pathways	Protease/Metabolic Enzyme
Targets	Cytochrome P450

The iron chelator Deferasirox causes severe mitochondrial swelling without depolarization due to a specific effect on inner membrane permeability Publications Citing of Biochempartner's Deferasirox(CAS:201530-41-8)

Publications Citing of Biochempartner's Deferasirox(CAS:201530-41-8)

Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.

For product details of different batches, please contact our Customer

Products are for research use only and not for human use. We do not sell to patients.